Progyny, INC Form 4 insider transactions

Geoffrey Clapp, Chief Product Officer of Progyny, Inc., reported a transaction in 819 shares of common stock on September 17, 2026.

Kevin K Gordon, a Director of Progyny, Inc., sold 11,500 shares of common stock on September 10, 2026 for $27.12 per share.

Kevin K Gordon, a Director of Progyny, Inc., sold 11,500 shares of common stock on September 10, 2026 for $27.94 per share.

Peter Anevski, CHIEF EXECUTIVE OFFICER and a Director of Progyny, Inc., reported a transaction in 5,361 shares of common stock on September 3, 2026.

Allison Swartz, EVP, GC of Progyny, Inc., reported multiple transactions in common stock on September 3, 2026.

Mark S. Livingston, CHIEF FINANCIAL OFFICER of Progyny, Inc., reported a transaction in 479 shares of common stock on September 4, 2026.

Mark S. Livingston, CHIEF FINANCIAL OFFICER of Progyny, Inc., reported multiple transactions in common stock on September 2, 2026.

Allison Swartz, EVP, GC of Progyny, Inc., reported a transaction in 1,352 shares of common stock on August 28, 2026.

Melissa B Cummings, Chief Operating Officer of Progyny, Inc., sold 2,244 shares of common stock on July 14, 2026 for $31.60 per share.

Progyny CFO Mark S. Livingston sold shares and withheld stock for tax obligations under a pre-established 10b5-1 plan.

Progyny EVP and General Counsel Allison Swartz reported the sale and tax-withholding disposition of common stock.

Progyny CEO Peter Anevski reported the withholding of 5,361 shares to cover tax obligations related to the vesting of restricted stock units.

Progyny's Chief Financial Officer, Mark S. Livingston, reported transactions involving the sale of company stock, including shares withheld for tax payments and shares sold under a pre-arranged trading plan.

Progyny Director Cheryl Scott reports transactions involving common stock and stock options, including acquisitions and dispositions.

Progyny Chief Product Officer Geoffrey Clapp executed a series of transactions involving Progyny, Inc. (PGNY) common stock on June 2, 2026.

Progyny, Inc. Director Elizabeth D. Bierbower acquired stock options and restricted stock units (RSUs) on May 21, 2026, as detailed in a Form 4 filing.

Progyny, Inc. Director Lloyd H. Dean reported the acquisition of 6,792 shares of common stock and 28,203 stock options on May 21, 2026.

Progyny, Inc. Director Kevin Gordon reported transactions involving common stock and stock options on May 21, 2026.

Progyny, Inc. Director Roger C. Holstein reported transactions involving common stock and stock options on May 21, 2026.

Progyny, Inc. Director Jeffrey G. Park acquired 7,924 shares of common stock and was granted stock options for 36,663 shares.

Progyny, Inc. Director Norman Payson reported transactions involving restricted stock units and stock options on May 21, 2026.

Progyny, Inc. Director Cheryl Scott reported a transaction involving the acquisition of common stock and stock options.

Debra L. Morris, a Director at Progyny, Inc., has acquired shares and stock options through a transaction on May 21, 2026.

Progyny's Chief Financial Officer, Mark S. Livingston, has sold 8,275 shares of common stock for $25.50 per share, totaling $210,987.50, as part of a pre-arranged trading plan.

Progyny's Chief Operating Officer, Melissa B. Cummings, sold 9,578 shares of common stock for $25 per share under a pre-arranged 10b5-1 trading plan.

Progyny, Inc. Chief Operating Officer Melissa Cummings reported the withholding of 4,172 shares to cover tax obligations upon the vesting of restricted stock units.

Progyny's Chief Product Officer, Geoffrey Clapp, reported a disposition of 3,275 shares of common stock at $17.42 per share for tax withholding purposes.

Progyny's EVP and General Counsel, Allison Swartz, sold 599 shares of common stock on March 4, 2026, under a pre-arranged 10b5-1 trading plan.

Progyny's Chief Financial Officer, Mark S. Livingston, disposed of 339 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Progyny's Chief Product Officer, Geoffrey Clapp, was granted 35,228 restricted stock units and 51,373 stock options as part of an annual merit award.